GenDx manufactures in vitro diagnostic software and reagents for HLA typing and chimerism monitoring in transplant settings. The tech stack (C#, Java, SQL Server, Azure AD) and active projects (HLA typing tool, chimerism monitoring, advanced molecular diagnostics software) reflect a regulated diagnostics vendor managing both clinical software and laboratory automation. Current hiring is operations-heavy with infrastructure and security initiatives dominating the roadmap—a pattern typical of companies tightening compliance posture ahead of or during regulatory tightening.
GenDx develops molecular diagnostic tools for solid organ and stem cell transplantation, with core products centered on high-resolution HLA typing by Next Generation Sequencing and chimerism monitoring. The company operates a global distribution model (approximately 40 partners) while maintaining direct customer support and training. Based in Utrecht, Netherlands, with roughly 90 employees, GenDx serves transplant centers and hospital labs across multiple geographies. The product combines reagent kits and proprietary software for donor–recipient matching and post-transplant surveillance.
GenDx uses C#, Java, SQL Server, Azure AD, and Hyper-V. For lab automation: qPCR and Sanger sequencing instruments. DevOps tools include Git, TeamViewer, OPNsense, and PDQ Deploy.
Active product development includes HLA typing tools, chimerism monitoring software, and advanced molecular diagnostics platforms. Current work also covers method validation, QC procedures, and infrastructure upgrades to meet NIS 2 and ISO 13485 compliance.
Other companies in the same industry, closest in size